EUVIMEDEUVIMED entdecken
Multizentrische Studie

The location and degree of residual disease determines recurrence patterns and survival in patients with esophageal adenocarcinoma after trimodal therapy

Weston G Andrews iD, Sandra Blitz, Marisa Sewell iD, Daniela Molena, Wayne L Hofstetter, Jonathan Yeung iD, Gail E Darling, Ahmed Sharata, Steven R DeMeester, Christian G Peyre, Colin Dunn, John C Lipham und 4 weitere

Diseases of the Esophagus · 2025

DOI: 10.1093/dote/doaf125 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Diseases of the Esophagus, 2025. Verfasst von Weston G Andrews und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Swedish Cancer Institute, Seattle, Washington, USA. Hauptthemen laut MEDLINE: Esophageal Neoplasms, Adenocarcinoma, Neoplasm Recurrence, Local, Esophagectomy. Die Arbeit nennt 23 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Known predictors of recurrence and survival include the total number of nodes and positive nodes resected, tumor stage, histology, and tumor differentiation. Patients with a complete response have the best survival, but residual tumor in the esophagus, nodes, or both may influence survival. This study assesses the risk of recurrence and survival of esophageal adenocarcinoma after trimodal therapy based upon the location residual disease in the resected specimen. Multicenter, retrospective study of patients with esophageal adenocarcinoma undergoing induction chemoradiation and transthoracic esophagectomy from 2010 to 2017. Overall survival (OS) and recurrence were compared based on the residual disease location using Kaplan–Meier analysis. Clinical factors associated with OS and time to recurrence were also assessed. There were 504 patients with a median follow-up of 63.4 months 95% confidence interval (CI):60.8–70.5 and an estimated overall 5-year survival of 55.8%. When subdivided by residual disease location, the estimated 5-year survival in patients with complete pathologic response and residual disease of only the esophagus was 68.3% and 65.0% hazard ratio (HR) = 1.05; P = 0.81. With increasing nodal positivity there was decreasing survival, 45.8% (N1) and 20.1% (N2). N3 patients did not survive past 36 months. Multivariable analysis demonstrates that any residual disease in the lymph nodes (HR = 3.14), taxane and fluoropyrimidine chemotherapy (HR = 3.34), neoadjuvant radiation dose <50 Gy (HR = 2.35), and fluoropyrimidine chemotherapy (HR = 1.88) were predictive of worse OS. Overall survival and recurrence are influenced by the location of residual disease. Residual disease in the esophagus and pathologic complete response behaves similarly. Survival is reduced as nodal counts increase.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Esophageal NeoplasmsAdenocarcinomaNeoplasm Recurrence, LocalEsophagectomyHumansMaleFemaleRetrospective StudiesNeoplasm, ResidualMiddle AgedAgedKaplan-Meier EstimateNeoadjuvant TherapyNeoplasm StagingLymphatic MetastasisAdultLymph Nodes

Stichwörter der Autor:innen

chemoradiationesophageal canceresophagectomyresidual esophageal adenocarcinomasurvival

Autor:innen und Institutionen

  • Department of Surgery, Swedish Cancer Institute, Seattle, Washington, USA.
  • Sandra Blitz Biostatistical Consulting Services, Kelowna, British Columbia, Canada.
  • Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York City, New York, USA.
  • Department of Thoracic and Cardiovascular Surgery, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA.
  • Department of Surgery, University of Toronto, Toronto, Ontario, Canada.
  • Department of Surgery, The Oregon Clinic, Portland, Oregon, USA.

ORCID-Profile: Weston G Andrews, Marisa Sewell, Jonathan Yeung, Brian E Louie

Zitieren

APA

Andrews, W. G., Blitz, S., Sewell, M., Molena, D., Hofstetter, W. L., Yeung, J., Darling, G. E., Sharata, A., DeMeester, S. R., Peyre, C. G., Dunn, C., Lipham, J. C., Bograd, A. J., White, P. T., Farivar, A. S., & Louie, B. E. (2025). The location and degree of residual disease determines recurrence patterns and survival in patients with esophageal adenocarcinoma after trimodal therapy. Diseases of the Esophagus. https://doi.org/10.1093/dote/doaf125

Vancouver

Andrews WG, Blitz S, Sewell M, Molena D, Hofstetter WL, Yeung J, et al. The location and degree of residual disease determines recurrence patterns and survival in patients with esophageal adenocarcinoma after trimodal therapy. Diseases of the Esophagus. 2025. doi:10.1093/dote/doaf125

BibTeX
@article{Andrews2025,
  author = {Andrews, Weston G and Blitz, Sandra and Sewell, Marisa and Molena, Daniela and Hofstetter, Wayne L and Yeung, Jonathan and Darling, Gail E and Sharata, Ahmed and DeMeester, Steven R and Peyre, Christian G and Dunn, Colin and Lipham, John C and Bograd, Adam J and White, Peter T and Farivar, Alexander S and Louie, Brian E},
  title = {The location and degree of residual disease determines recurrence patterns and survival in patients with esophageal adenocarcinoma after trimodal therapy},
  journal = {Diseases of the Esophagus},
  year = {2025},
  doi = {10.1093/dote/doaf125}
}
Kostenlos starten →